Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Jefferies Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 3:47 PM EDTJefferies analyst Roger Song downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold with a price target of $1.50 (from $11.00).
The analyst comments "We spoke w/ mgmt following IDMC demonstrated nab-sirolimus (mTOR) tumor agonostic pivotal in TSC1/TSC2 tumors was unlikely to... More
TD Cowen Downgrades Aadi Bioscience Inc (AADI) to Hold
August 21, 2024 4:47 AM EDTTD Cowen analyst Boris Peaker downgraded Aadi Bioscience Inc (NASDAQ: AADI) from Buy to Hold.
The analyst comments "Aadi management announced that the PRECISION1 trial in TSC1/2 solid tumors will be discontinued due to low probability of meeting the efficacy threshold needed for accelerated... More



